Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W C Shakespeare

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current Opinion in Chemical Biology|July 27, 2001
SH2 domain inhibition: a problem solved?W C Shakespeare
Current Opinion in Drug Discovery & Development|August 4, 2009
Signal transduction drug discovery: targets, mechanisms and structure-based designD C Dalgarno, C A Metcalf, W C Shakespeare, et al.
Chemistry & Biology|November 18, 1998
A novel mechanism-based mammalian cell assay for the identification of SH2-domain-specific protein-protein inhibitorsR J Rickles, P A Henry, W Guan, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|July 1, 1996
ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in ratsZ G Zhang, D Reif, J Macdonald, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 1999
An efficient synthesis of a 4'-phosphonodifluoromethyl-3'-formyl-phenylalanine containing SRC SH2 ligandW C Shakespeare, R S Bohacek, S S Narula, et al.
Chemistry & Biology|March 14, 2000
A Src SH2 selective binding compound inhibits osteoclast-mediated resorptionS M Violette, W C Shakespeare, C Bartlett, et al.
Journal of Medicinal Chemistry|October 29, 2000
Structure-based design of novel bicyclic nonpeptide inhibitors for the src SH2 domainW C Shakespeare, R S Bohacek, M D Azimioara, et al.
British Journal of Cancer|May 11, 2006
Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinasesD P Lesslie, J M Summy, N U Parikh, et al.
Journal of Medicinal Chemistry|May 23, 1998
Modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biological diversity. A new route to ether synthesisR Hirschmann, J Hynes, M A Cichy-Knight, et al.
Journal of Medicinal Chemistry|March 23, 2001
X-Ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitorR S Bohacek, D C Dalgarno, M Hatada, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Opinion in Chemical Biology|July 27, 2001
SH2 domain inhibition: a problem solved?W C Shakespeare
Current Opinion in Drug Discovery & Development|August 4, 2009
Signal transduction drug discovery: targets, mechanisms and structure-based designD C Dalgarno, C A Metcalf, W C Shakespeare, et al.
Chemistry & Biology|November 18, 1998
A novel mechanism-based mammalian cell assay for the identification of SH2-domain-specific protein-protein inhibitorsR J Rickles, P A Henry, W Guan, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|July 1, 1996
ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in ratsZ G Zhang, D Reif, J Macdonald, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 1999
An efficient synthesis of a 4'-phosphonodifluoromethyl-3'-formyl-phenylalanine containing SRC SH2 ligandW C Shakespeare, R S Bohacek, S S Narula, et al.
Chemistry & Biology|March 14, 2000
A Src SH2 selective binding compound inhibits osteoclast-mediated resorptionS M Violette, W C Shakespeare, C Bartlett, et al.
Journal of Medicinal Chemistry|October 29, 2000
Structure-based design of novel bicyclic nonpeptide inhibitors for the src SH2 domainW C Shakespeare, R S Bohacek, M D Azimioara, et al.
British Journal of Cancer|May 11, 2006
Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinasesD P Lesslie, J M Summy, N U Parikh, et al.
Journal of Medicinal Chemistry|May 23, 1998
Modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biological diversity. A new route to ether synthesisR Hirschmann, J Hynes, M A Cichy-Knight, et al.
Journal of Medicinal Chemistry|March 23, 2001
X-Ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitorR S Bohacek, D C Dalgarno, M Hatada, et al.
Pageof 2